Pharmacokinetics, safety, and tolerability of PSI 7851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects

Trial Profile

Pharmacokinetics, safety, and tolerability of PSI 7851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2012

At a glance

  • Drugs PSI 7851 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Pharmasset
  • Most Recent Events

    • 09 Jun 2009 Status changed from recruiting to completed, according to a Pharmasset media release.
    • 20 Apr 2009 The first antiviral data are expected to be reported in the second half of 2009, according to a Pharmasset media release.
    • 06 Apr 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top